Caiding Xu, Chief Technology Officer
Professional Overview
Caiding Xu is an accomplished pharmaceutical and biotechnology executive with over a decade of experience driving innovation and strategic technology initiatives. As the Chief Technology Officer at Apeloa Pharmaceutical Co., Ltd., he is responsible for leading the company's research and development efforts, overseeing the implementation of cutting-edge technologies, and spearheading the development of novel drug candidates.
Experience Summary
Current Role
As the Chief Technology Officer at Apeloa Pharmaceutical Co., Ltd. since April 2024, Caiding Xu is instrumental in shaping the company's technological roadmap and guiding its R&D activities. In this role, he is responsible for:
- Providing strategic direction and oversight for the company's research and development initiatives
- Driving the implementation of innovative technological solutions to enhance drug discovery, manufacturing, and quality assurance processes
- Fostering cross-functional collaboration to accelerate the development and commercialization of Apeloa's drug pipeline
- Establishing partnerships with academic institutions and industry leaders to leverage the latest scientific advancements
Career Progression
Prior to his current role, Caiding Xu held several senior-level positions in the pharmaceutical and biotechnology industry. From 2018 to 2024, he served as the Vice President of CMC Development at Pegbio Co., Ltd., where he led the company's chemistry, manufacturing, and controls (CMC) strategies, ensuring the successful advancement of multiple drug candidates through the development pipeline. Before that, he was the Vice President of Peptide R&D at CPC from 2014 to 2018, where he spearheaded the development of novel peptide-based therapeutics.
Caiding's early career was marked by roles as a Research Fellow at Protagonist Therapeutics and a Senior Scientist II in Manufacturing & CMC Development at Affymax, Inc., where he gained valuable experience in drug discovery, process development, and regulatory compliance.
Academic Background
Caiding Xu holds a Ph.D. in Pharmaceutical Sciences from the University of California, San Francisco, with a specialization in peptide chemistry and drug delivery. He has published numerous peer-reviewed articles and presented at various industry conferences, demonstrating his expertise and thought leadership in the pharmaceutical and biotechnology fields.
Areas of Expertise
- Innovative drug discovery and development strategies
- Peptide and protein therapeutics
- Chemistry, manufacturing, and controls (CMC) optimization
- Process development and scale-up
- Regulatory compliance and quality assurance
- Cross-functional team leadership and strategic planning
Professional Impact
Throughout his career, Caiding Xu has played a pivotal role in advancing the development of several successful drug candidates. At Pegbio Co., Ltd., he led the CMC efforts for a novel biologic that received FDA approval, significantly contributing to the company's growth and market success. At CPC, he spearheaded the development of a first-in-class peptide-based therapy that is currently in late-stage clinical trials, positioning the company as a leader in the field of peptide therapeutics.
Conclusion
Caiding Xu's extensive experience and proven track record in the pharmaceutical and biotechnology industries make him a valuable asset to Apeloa Pharmaceutical Co., Ltd. As the Chief Technology Officer, he is poised to drive the company's technological innovation, accelerate the development of its drug pipeline, and contribute to its long-term success in the highly competitive global market.
